Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have
Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer. If you join this study, you will receive a new experimental drug named SGN-LIV1A or ladiratuzumab vedotin (LV). In addition, this trial uses another drug that is approved in the United States for other forms of cancer, but not for breast cancer. This drug is called pembrolizumab,). The purpose of this research study is to Evaluate the safety and tolerability of the combination of ladiratuzumab vedotin (LV; SGN-LIV1A) and pembrolizumab in patients with locally-advanced or metastatic triple-negative breast cancer (LA/M TNBC).

If you take part in this trial, you will receive both drugs. If your cancer is stable or gets better, you may get up to 35 cycles (about 2 years) of treatment with pembrolizumab. There is no set limit for how many cycles of SGN-LIV1A you can receive.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03310957

Contact Name: uvacancertrials@hscmail.mcc.virginia.edu